IP Verse

Method For Preventing Or Treating Osteoporosis Characterized By Administering Teriparatide Or Salt Thereof Twice A Week - EP3875105

The patent EP3875105 was granted to Asahi Kasei Pharma on Nov 27, 2024. The application was originally filed on Jul 31, 2019 under application number EP19879778A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3875105

ASAHI KASEI PHARMA
Application Number
EP19879778A
Filing Date
Jul 31, 2019
Status
Granted And Under Opposition
Oct 25, 2024
Publication Date
Nov 27, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 27, 2025ELKINGTON AND FIFEADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONJPH0873376
DESCRIPTIONWO0010596
DESCRIPTIONWO2011030774
SEARCHUS2002007140
SEARCHUS5616560

Non-Patent Literature (NPL) Citations (38) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- "Acute development of cortical porosity and endosteal naive bone formation from the daily but not weekly short-term administration of PTH in rabbit", PLOS ONE, vol. 12, no. 4, page e0175329
DESCRIPTION- Adv Ther, (20170000), vol. 34, pages 1727 - 1740
DESCRIPTION- Arch Osteoporos, (20180000), vol. 13, no. 1, page 54
DESCRIPTION- Bone, (20090000), vol. 45, pages 1053 - 1058
DESCRIPTION- BoneKEy Rep, (20140000), vol. 3, no. 512
DESCRIPTION- Calcif Tissue Int, (20140000), vol. 94, pages 170 - 175
DESCRIPTION- Endocrine Reviews, (19890000), vol. 10, no. 4, pages 420 - 436
DESCRIPTION- "Iyakuhin no Fukusayo no Jutokudo Bunrui Kijun nitsuite", Classification Criteria for Degree of Seriousness of Side Effects of Pharmaceuticals, (19920629), no. 80
DESCRIPTION- JAMA, (20010000), vol. 285, no. 6, pages 785 - 795
DESCRIPTION- JAPI, (20080000), vol. 56, pages 418 - 424
DESCRIPTION- J Bone Miner Metab, (20040000), vol. 22, pages 104 - 110
DESCRIPTION- J Bone Miner Metab, (20080000), vol. 26, pages 624 - 634
DESCRIPTION- JBone Miner Res, (19930000), vol. 8, pages 1137 - 1148
DESCRIPTION- J Clin Endocrinol Metab, (20120000), vol. 97, no. 9, pages 3097 - 3106
DESCRIPTION- Journal of Japanese Society for Bone Morphometry, (20180000), vol. 28, pages 31 - 37
DESCRIPTION- KAGOSHIMA-SHI IHO, "Yakuzai Netsu nitsuite (Drug Fever", JOURNAL OF THE KAGOSHIMA CITY MEDICAL ASSOCIATION, (20060000), vol. 45, no. 9
DESCRIPTION- Kawasaki Medical Journal, (20100000), vol. 36, no. 2, pages 153 - 157
DESCRIPTION- "Kotsusoshoshouyou Yaku no Rinsho Hyokahoho ni Kansuru Gaidorain no Kaitei nitsuite (Revision on Guidelines on Clinical Assessment Method for Drugsfor Osteoporosis)", Yaku-sei-yaku-shin-hatsu (Pharmaceutical Sanitation Bureau Drug Examination Management Notification) 0707, (20170000), no. 1
DESCRIPTION- N Engl J Med, (20010000), vol. 344, no. 19, pages 1434 - 1441
DESCRIPTION- Osteoporos Int, (19950000), vol. 5, pages 354 - 370
DESCRIPTION- Osteoporos Int, (19990000), vol. 9, pages 296 - 306
DESCRIPTION- "Pharmaceutical Interview Form Japan Standard Goods Classification Number", Iyakuhin Intabyu Fohm Nihon Hyojun Shohin Bunrui Bango, no. 872439
DESCRIPTION- The Journal of the Japanese Society of Internal Medicine, (20120000), vol. 101, no. 4, pages 1007 - 1014
INTERNATIONAL-SEARCH-REPORT- Hagino Hiroshi, "Uses of Novel Drug Treatment for Osteoporosis ''Weekly-Administered Teriparatide Preparation'' (Teribone Hypodermic Injection 56.5 g) for the Elderly", Progress in Medicine, (20111130), vol. 32, no. 2, ISSN 0287-3648, pages 373 - 378, XP009525939 [X] 1, 4 [A] 2-3
INTERNATIONAL-SEARCH-REPORT- Takakura Aya , "Higher Frequencies of Teriparatide develops Cortical Porosity", Journal of Japanese Society of Bone Morphometry, (20180320), vol. 28, no. 1, ISSN 0917-4648, pages 31 - 37, XP009525938 [Y] 1, 4 [A] 2-3
INTERNATIONAL-SEARCH-REPORT- Tanaka Shinya , "Q&A to Aid Clinical Practice: Teach Us about Drug Treatments for Osteoporosis that are Under Development", Geriatric Medicine, (2018130), vol. 56, no. 12, ISSN 0387-1088, pages 1225 - 1230, XP009525937 [PX] 1, 4
INTERNATIONAL-SEARCH-REPORT- KUMAGAI, Y. et al., "Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study", Clinical Pharmacology in Drug Development, (20190328), ISSN 2160-7648, XP055703803 [PX] 1-4
INTERNATIONAL-SEARCH-REPORT- FUJITA, T. et al., "Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels", Osteoporosis International, (19990000), vol. 9, no. 4, doi:10.1007/s001980050151, ISSN 0937-941X, pages 296 - 306, XP055050510 [Y] 1, 4 * , in particular, p. 296, Abstract, fig. 1, table 6 * [A] 2-3
INTERNATIONAL-SEARCH-REPORT- TAKAKURA, AYA et al., "Administration frequency as well as dosage of PTH are associated with development of cortical porosity in ovariectomized rats", Bone Research, (20170000), vol. 5, no. 17002, ISSN 2095-4700, XP055703806 [Y] 1, 4 * , in particular, fig. 2 * [A] 2-3
INTERNATIONAL-SEARCH-REPORT- Ryuichi Kato , Tetsuya Kamataki, "Toxicity and Safety of Drugs", Chemical Education, (19830420), vol. 31, no. 2, doi:10.20665/kagakukyouiku.31.2_97, ISSN 0386-2151, pages 97 - 101, XP055779701 [Y] 1, 4
OPPOSITION- Anonymous, "Asahi Kasei osteoporosis drug gets Japanese approval ", Pharmaceutical Business Review, (20110926), Pharmaceutical Business Review, URL: https://www.pharmaceutical-business-review.com/news/asahi-kasei-osteoporosis-drug-gets-japanese-approval-260911/, XP093312785
OPPOSITION- Anonymous, "FORTEO (teriparatide [rDNA origin] injection) for subcutaneous use - Highlights of Prescribing Information", FDA, (20161001), XP093312783
OPPOSITION- John H. Collett, Soraya Dhillon, "DOSAGE REGIMENS", Aulton's Pharmaceutics: The Design and Manufacture of Medicines Fourth edition, Elsevier Ltd., (20130101), pages 2pp, 355 - 366, XP055794776
OPPOSITION- Kim Kyoung Min, Lee Sae Young, Rhee Yumie, "Influence of Dosing Interval and Administration on the Bone Metabolism, Skeletal Effects, and Clinical Efficacy of Parathyroid Hormone in Treating Osteoporosis: A Narrative Review", JBMR Plus, (20170801), vol. 1, no. 1, doi:10.1002/jbm4.10005, ISSN 2473-4039, pages 36 - 45, XP093312788
OPPOSITION- Fujita Takuo, Fukunaga Masao, Itabashi Akira, Tsutani Kiichiro, Nakamura Toshitaka, "Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis", CALCIFIED TISSUE INTERNATIONAL, NEW YORK, NY, US, US , (20140201), vol. 94, no. 2, doi:10.1007/s00223-013-9777-8, ISSN 0171-967X, pages 170 - 175, XP093312786
OPPOSITION- Donovan Tay et al, "Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology", Br J Clin Pharmacol, (2018), vol. 84, doi:10.1111/bcp.13455, XP009506455
OPPOSITION- Kenkre Js, Bassett Jhd, "The bone remodelling cycle", Annals of clinical biochemistry, BRITISH MEDICAL ASSOCIATION, LONDON., GB, GB , (20180501), vol. 55, no. 3, doi:10.1177/0004563218759371, ISSN 0004-5632, pages 308 - 327, XP093312789
OPPOSITION- Nakamura Toshitaka, Sugimoto Toshitsugu, Nakano Tetsuo, Kishimoto Hideaki, Ito Masako, Fukunaga Masao, Hagino Hiroshi, Sone Teruki, Yoshikawa Hideki, Nishizawa Yoshiki, Fujita Takuo, Shiraki Masataka, "Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk", Journal of Clinical Endocrinology and Metabolism, The Endocrine Society, US, US , (20120901), vol. 97, no. 9, doi:10.1210/jc.2011-3479, ISSN 0021-972X, pages 3097 - 3106, XP093312787

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents